As of this week, consumers can get a generic version of Lipitor, the best-selling drug developed by Pfizer.
Heralding this fact, in the mainstream press as well as in the business press, are the kinds of praises and exultations one usually hears only on Oscar night.
Forbes.com’s Avik Roy, in his blog (The Apothecary) points to several of these http://www.forbes.com/sites/aroy/2011/11/30/lipitor-is-dead-long-live-lipitor/ .
One of the most interesting is certainly that by Paul Howard in “Medical Progress Today,” who offers a detailed accounting, and reminder, of how dramatically Lipitor has changed the nation’s cardiovascular landscape http://www.medicalprogresstoday.com/2011/11/the-end-of-the-age-of-lipitor.php.
Create more CT Mirror journalism.
The Connecticut Mirror is a nonprofit newsroom. 88% of our revenue comes from readers like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you publish it.
Want more in-depth Connecticut reporting?
Get CT Mirror briefings with enterprise reporting, investigations and more in your inbox daily.
Free to Read. Not Free to Produce.
The Connecticut Mirror is a nonprofit newsroom. 88% of our revenue comes from readers like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you publish it.